Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
Georgina V. Long(The University of Sydney), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), John M. Kirkwood(UPMC Hillman Cancer Center), Luis de la Cruz‐Merino, Charles H. Yoon(Brigham and Women's Hospital), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Xi Wu(Chinese Academy of Sciences), Dirk Schadendorf(National Center for Tumor Diseases), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Federica De Galitiis(Istituto Dermopatico dell'Immacolata), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Alexander M.M. Eggermont(University Medical Center Utrecht), Francesco Spagnolo(Martin University), Jean‐Jacques Grob(Aix-Marseille Université), Jason J. Luke(University of Chicago), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Matteo S. Carlino(The University of Sydney), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), Jacek Mackiewicz(Poznan University of Medical Sciences), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Muhammad A. Khattak, Mizuho Fukunaga‐Kalabis(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 149
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k